Polaryx Therapeutics names Will Charlton chief medical officer
PLYX•Chief medical officer appointment
- Polaryx Therapeutics named Will Charlton chief medical officer, effective Sept. 1, 2026.
- The appointment positions the company for a planned SOTERIA Phase 2 trial initiation in Q4 2026.
- Charlton previously served as SVP of clinical development, skeletal dysplasia at Tyra Biosciences.
- He also held chief medical officer roles, including at Spruce Biosciences, focused on pediatric rare-disease development.
